ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 161 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2017. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,948,344 | -55.8% | 54,652 | -42.9% | 0.00% | 0.0% |
| Q2 2023 | $4,412,104 | +8.5% | 95,645 | -5.7% | 0.00% | 0.0% |
| Q1 2023 | $4,066,702 | +41019.3% | 101,414 | -52.5% | 0.00% | -66.7% |
| Q4 2022 | $9,890 | -99.9% | 213,533 | -0.1% | 0.00% | 0.0% |
| Q3 2022 | $8,846,000 | -57.8% | 213,650 | -39.2% | 0.00% | -62.5% |
| Q2 2022 | $20,956,000 | -37.8% | 351,252 | -24.3% | 0.01% | -20.0% |
| Q1 2022 | $33,693,000 | +24.4% | 463,996 | +44.1% | 0.01% | +25.0% |
| Q4 2021 | $27,081,000 | +32.7% | 322,051 | +42.3% | 0.01% | +14.3% |
| Q3 2021 | $20,401,000 | +25.7% | 226,256 | +32.9% | 0.01% | +40.0% |
| Q2 2021 | $16,229,000 | -14.5% | 170,191 | +2.1% | 0.01% | -16.7% |
| Q1 2021 | $18,990,000 | -60.4% | 166,657 | -51.9% | 0.01% | -64.7% |
| Q4 2020 | $47,979,000 | +58.0% | 346,541 | -6.2% | 0.02% | +30.8% |
| Q3 2020 | $30,364,000 | -0.4% | 369,375 | -5.2% | 0.01% | 0.0% |
| Q2 2020 | $30,480,000 | +67.9% | 389,793 | -4.6% | 0.01% | +44.4% |
| Q1 2020 | $18,149,000 | +14.9% | 408,518 | +10.4% | 0.01% | +50.0% |
| Q4 2019 | $15,797,000 | +16.9% | 369,869 | +17.1% | 0.01% | +20.0% |
| Q3 2019 | $13,517,000 | +31.5% | 315,968 | +95.2% | 0.01% | +25.0% |
| Q2 2019 | $10,280,000 | +7.1% | 161,909 | +17.0% | 0.00% | 0.0% |
| Q1 2019 | $9,597,000 | +61.7% | 138,379 | +1.3% | 0.00% | +33.3% |
| Q4 2018 | $5,936,000 | +25.5% | 136,555 | +120.4% | 0.00% | +50.0% |
| Q3 2018 | $4,729,000 | +705.6% | 61,947 | +711.4% | 0.00% | – |
| Q2 2018 | $587,000 | -49.3% | 7,635 | -55.3% | 0.00% | -100.0% |
| Q1 2017 | $1,158,000 | +46.0% | 17,092 | +51.6% | 0.00% | – |
| Q4 2016 | $793,000 | -87.6% | 11,276 | -80.3% | 0.00% | -100.0% |
| Q4 2015 | $6,414,000 | +28.1% | 57,172 | +9.9% | 0.00% | +33.3% |
| Q3 2015 | $5,007,000 | +116.0% | 52,033 | +129.6% | 0.00% | +200.0% |
| Q2 2015 | $2,318,000 | – | 22,658 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |